We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY.RT
126
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$2.46M 0.04%
+816,600
New +$2.12M
PFE icon
127
Pfizer
PFE
$140B
$2.35M 0.04%
63,240
+21,080
+50% +$751K
KURA icon
128
Kura Oncology
KURA
$922M
$2.17M 0.03%
157,800
-8,500
-5% -$126K
MRTX
129
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.1M 0.03%
16,300
+400
+3% +$38.6K
QURE icon
130
uniQure
QURE
$2.68B
$2.07M 0.03%
28,900
-2,000
-6% -$110K
SRPT icon
131
Sarepta Therapeutics
SRPT
$1.66B
$2M 0.03%
+15,500
New +$1.56M
BNFT
132
DELISTED
Benefitfocus, Inc.
BNFT
$1.99M 0.03%
90,463
– –
CTLT
133
DELISTED
CATALENT, INC.
CTLT
$1.93M 0.03%
34,300
-3,200
-9% -$163K
ACAD icon
134
Acadia Pharmaceuticals
ACAD
$4.25B
$1.71M 0.03%
40,000
-50,400
-56% -$2.19M
KYNB
135
Kyntra Bio
KYNB
$28.5M
$1.65M 0.03%
+1,540
New +$1.57M
FATE icon
136
Fate Therapeutics
FATE
$281M
$1.62M 0.03%
82,800
+22,700
+38% +$360K
BPMC
137
DELISTED
Blueprint Medicines
BPMC
$1.62M 0.03%
20,200
+4,400
+28% +$329K
LGND icon
138
Ligand Pharmaceuticals
LGND
$6.02B
$1.62M 0.03%
+24,847
New +$1.66M
VTRS icon
139
Viatris
VTRS
$20.1B
$1.61M 0.03%
80,000
-213,200
-73% -$3.97M
BLUE
140
DELISTED
bluebird bio
BLUE
$1.61M 0.03%
+1,413
New +$1.54M
BIB icon
141
ProShares Ultra NASDAQ Biotechnology
BIB
$82.2M
$1.54M 0.02%
+25,000
New +$1.33M
A icon
142
Agilent Technologies
A
$39.1B
$1.54M 0.02%
18,000
-11,800
-40% -$929K
STIM icon
143
Neuronetics
STIM
$120M
$1.46M 0.02%
325,961
– –
AMRX icon
144
Amneal Pharmaceuticals
AMRX
$5.72B
$1.45M 0.02%
+300,000
New +$1.04M
ZGNX
145
DELISTED
Zogenix, Inc.
ZGNX
$1.36M 0.02%
26,100
+3,100
+13% +$142K
XLRN
146
DELISTED
Acceleron Pharma
XLRN
$1.28M 0.02%
24,200
-1,600
-6% -$73K
RGEN icon
147
Repligen
RGEN
$7.44B
$1.26M 0.02%
+13,600
New +$1.14M
BHVN
148
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.24M 0.02%
+22,700
New +$1.12M
GWPH
149
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.17M 0.02%
11,200
+747
+7% +$83.8K
LH icon
150
Labcorp
LH
$24.3B
$935K 0.01%
6,432
-55
-0.8% -$7.94K
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.